ABSTRACT
To date, cancer continues to be one of the biggest challenges for medical science. Nanotechnology has enabled us to overcome some of the limitations of conventional treatment in lung cancer therapeutics. Recently, US Food and Drug Administration (FDA) has approved certain nanomedicines for clinical administration against lung cancer. This article presents a narrative review of approved nanomedicines in lung cancer with a special focus on the results of recently concluded and ongoing clinical trials. The limitations associated with using nanomaterials as anti-lung cancer therapeutic agents and the possible mechanisms to overcome these limitations are also discussed.
ABSTRACT
Installation of decentralized units for biogas production along with indigenous upgradation systems can be an effective approach to meet growing energy demands of the rural population. Therefore, readily available leaf waste was used to prepare biochar at different temperatures and employed for H2S removal from biogas produced via anaerobic digestion plant. It is found that biochar prepared via carbonization of leaf waste at 400⯰C effectively removes 84.2% H2S (from 1254â¯ppm to 201â¯ppm) from raw biogas for 25â¯min in a continuous adsorption tower. Subsequently, leaf waste biochar compositional, textural and morphological properties before and after H2S adsorption have been analyzed using proximate analysis, CHNS, BET surface area, FTIR, XRD, and SEM-EDX. It is found that BET surface area, pore size, and textural properties of leaf waste biochar plays a crucial role in H2S removal from the biogas.
